Clinical Trial

A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The main objective of the study is to determine the recommended phase 2 dose (RP2D) of Azercabtagene zapreleucel (azer-cel).
Protocol Amendment History 3 changes
notable Enrollment increased: 32 -> 100 participants 2026-05-19
notable Primary completion pushed: 2026-12-01 -> 2027-12-01 2026-05-19
minor Completion pushed: 2029-01-01 -> 2030-01-01 2026-05-19
Trial Details
NCT Number NCT06680037
Lead Sponsor TG Therapeutics, Inc.
Conditions B-cell Mediated Autoimmune Disorders
Enrollment 100 participants
Start Date 2025-05-06
Primary Completion 2027-12-01 (estimated)
Study Completion 2030-01-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-20